(-0.89%) 5 026.45 points
(-1.25%) 37 980 points
(-1.30%) 15 508 points
(-0.24%) $82.61
(-0.42%) $1.646
(0.05%) $2 339.50
(-0.06%) $27.33
(0.26%) $918.15
(-0.21%) $0.933
(0.00%) $10.98
(-0.32%) $0.800
(-0.06%) $92.26
@ $6.86
Issued: 14 Feb 2024 @ 15:49
Return: -37.68%
Previous signal: Feb 14 - 09:30
Previous signal:
Return: 2.01 %
Live Chart Being Loaded With Signals
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence...
Stats | |
---|---|
Today's Volume | 477 296 |
Average Volume | 723 462 |
Market Cap | 512.74M |
EPS | $0 ( 2024-03-14 ) |
Next earnings date | ( $-0.470 ) 2024-05-09 |
Last Dividend | $0.800 ( 2019-09-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.960 |
ATR14 | $0.0120 (0.28%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-29 | Marrazzo Jeffrey D | Buy | 250 000 | Stock Option (right to buy) |
2024-02-20 | Gv 2023 Gp, L.l.c. | Buy | 0 | Common Stock |
2024-02-25 | Gottesdiener Keith Michael | Buy | 100 000 | Stock Option (right to buy) |
2024-02-21 | Brudnick Richard | Buy | 135 747 | Stock Option (right to buy) |
2024-02-21 | Duffield Jeremy | Buy | 180 995 | Stock Option (right to buy) |
INSIDER POWER |
---|
34.54 |
Last 97 transactions |
Buy: 38 299 882 | Sell: 27 394 093 |
Volume Correlation
First Trust Heitman Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
First Trust Heitman Correlation - Currency/Commodity
First Trust Heitman Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-4.65M (0.00 %) |
EPS: | $-2.18 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-1.25M (0.00 %) |
EPS: | $-0.670 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-4.37M (0.00 %) |
EPS: | $-0.550 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-4.59M (0.00 %) |
EPS: | $-0.470 |
Financial Reports:
No articles found.
First Trust Heitman Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.0900 | 2015-12-23 |
Last Dividend | $0.800 | 2019-09-10 |
Next Dividend | $0 | N/A |
Payout Date | 2019-09-12 | |
Next Payout Date | N/A | |
# dividends | 15 | -- |
Total Paid Out | $3.83 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 1.65 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -1.022 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.937 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 2.53 | 0.800 | 2.33 | 1.864 | [1 - 3] |
quickRatioTTM | 2.16 | 0.800 | 2.02 | 1.617 | [0.8 - 2.5] |
cashRatioTTM | 0.737 | 1.500 | 7.02 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.0703 | -1.500 | 8.83 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 440.77 | 1.000 | 10.00 | 10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.699 | 2.00 | -0.566 | -1.132 | [0 - 30] |
freeCashFlowPerShareTTM | -1.788 | 2.00 | -0.894 | -1.788 | [0 - 20] |
debtEquityRatioTTM | 0.102 | -1.500 | 9.59 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -12.13 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 0.156 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -2.31 | 1.000 | -0.334 | 0 | [1 - 100] |
returnOnEquityTTM | -0.937 | 2.50 | -7.41 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.788 | 2.00 | -0.596 | -1.788 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.699 | 2.00 | -0.566 | -1.132 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.0663 | 1.500 | -2.89 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.950 |
First Trust Heitman
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators